Zacks: Analysts Set $111.67 Target Price for China Biologic Products Holdings, Inc. (CBPO)

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $111.67 for the company and are predicting that the company will post $1.11 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 193 out of 265 based on the ratings given to its competitors.

CBPO has been the topic of several analyst reports. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. BidaskClub upgraded China Biologic Products from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 20th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in shares of China Biologic Products by 41.2% in the third quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock valued at $274,000 after acquiring an additional 865 shares in the last quarter. California Public Employees Retirement System lifted its position in shares of China Biologic Products by 3.1% in the second quarter. California Public Employees Retirement System now owns 29,500 shares of the biopharmaceutical company’s stock valued at $3,336,000 after acquiring an additional 900 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of China Biologic Products in the fourth quarter valued at about $117,000. Cubist Systematic Strategies LLC lifted its position in shares of China Biologic Products by 73.2% in the third quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 1,952 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of China Biologic Products by 16.3% in the third quarter. First Trust Advisors LP now owns 18,814 shares of the biopharmaceutical company’s stock valued at $1,736,000 after acquiring an additional 2,641 shares in the last quarter. Institutional investors own 52.34% of the company’s stock.

China Biologic Products (NASDAQ CBPO) opened at $79.10 on Monday. The firm has a market capitalization of $2,620.58, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.00 and a beta of 1.67. China Biologic Products has a 52-week low of $72.21 and a 52-week high of $120.46.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/zacks-analysts-set-111-67-target-price-for-china-biologic-products-holdings-inc-cbpo.html.

About China Biologic Products

China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply